All News

8 November 2011

Celldex Therapeutics Announces Initiation of Phase 1 Clinical Trial of CDX-1127Antibodies

8 November 2011

Abbott Reports Five-Year Data for HUMIRA® (Adalimumab) in Ankylosing SpondylitisAntibodies

8 November 2011

Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite EndpointAntibodies

8 November 2011

FDA Approves ERBITUX® (cetuximab) for First-Line Recurrent Locoregional or Metastatic Head and Neck Cancer in Combination with Platinum-based Chemotherapy with 5-FluorouracilAntibodies

7 November 2011

Baxter Presents Phase III HyQ Efficacy and Tolerability Data at American College of Allergy, Asthma & Immunology MeetingAntibodies

7 November 2011

Abbott Presents HUMIRA® (Adalimumab) Phase 3 Study Results for Patients with Active Non-Radiographic Axial SpondyloarthritisAntibodies

7 November 2011

Data Showed ACTEMRA Monotherapy Significantly Improved Signs and Symptoms of Rheumatoid ArthritisAntibodies

7 November 2011

Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood ArthritisAntibodies

7 November 2011

Health of Patients with Nonalcoholic Steatohepatitis Improved Through Treatment with Anti-CD3 AntibodiesAntibodies

7 November 2011

New Sirukumab (CNTO 136) Phase 2 Data Show Efficacy of Interleukin-6 Inhibitor Across Multiple Dose Regimens in Treatment of Rheumatoid ArthritisAntibodies

7 November 2011

Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Six Years With Similar Safety Profile Observed in Original Fracture TrialAntibodies

7 November 2011

Treatment With Enbrel® (etanercept) Shows Significant and Sustained Clinical Benefits in Rheumatoid Arthritis (RA) Patients With Moderately Active DiseaseAntibodies

5 November 2011

FGI Successfully Completes Phase 1A First-in-Human Clinical TrialAntibodies

4 November 2011

FDA Approves U.S. Market Return for octagam® Following Octapharma’s Implementation of Enhanced Safety MeasuresAntibodies

4 November 2011

Ablynx regains rights from Pfizer to nanobodies targeting TNF-alphaAntibodies

3 November 2011

ImmunoGen, Inc. Earns Milestone From Amgen With IND AchievementAntibodies

2 November 2011

Immunomedics Announces FDA Allows Resumption of Clivatuzumab Tetraxetan Clinical TrialAntibodies

1 November 2011

biOasis Transcend Vector Delivers an Anti-Amyloid Beta (Aß) Antibody To The BrainAntibodies

31 October 2011

Circadian Receives FDA IND Approval to Begin Clinical Trials With VGX-100 for the Treatment of Cancer Patients With Solid TumorsAntibodies

31 October 2011

YM BioSciences Nimotuzumab Results Reported at SIOP ConferenceAntibodies

28 October 2011

ATLAB Pharma and BZL Biologics Announce Exclusive Global Licensing Agreement for Lu-J591, a Novel Radiopharmaceutical in Phase IIB for the Treatment of Prostate CancerAntibodies

26 October 2011

Anthera Announces Last Patient Enrolled in PEARL-SC StudyAntibodies

26 October 2011

Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimer’s Disease and Other ProteinopathiesAntibodies

25 October 2011

MolMed Expands Phase III Trial of NGR-hTNF for the Treatment of Mesothelioma in the United StatesAntibodies

25 October 2011

Seattle Genetics Announces Initiation of a Phase II Clinical Trial of ADCETRIS™ in CD30-Positive Non-Lymphoma MalignanciesAntibodies

24 October 2011

Elusys Initiates Third Clinical Safety Study of Anthim, a New Anthrax Treatment; Company Successfully Completes Manufacturing at Commercial ScaleAntibodies

24 October 2011

Thallion Pharmaceuticals Inc.: Blinded Results From Low Dose Cohort of Phase II SHIGATEC Trial Presented at IDSA Annual MeetingAntibodies

24 October 2011

Alemtuzumab (Lemtrada™*) Significantly Reduces Relapses in Multiple Sclerosis vs Interferon Beta-1a in a Phase III StudyAntibodies

24 October 2011

Novartis Phase II data show AIN457 provided rapid and significant relief of symptoms in up to 81% of patients with psoriasisAntibodies

21 October 2011

Xencor Initiates Phase 1 Study of XmAb5871 Therapeutic Antibody for the Treatment of Autoimmune DiseasesAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

Mesothelin-Targeted Immunotherapy Pipeline Review

T-Cell & NK-Cell Engaging Bispecific Antibodies 2019: a business, stakeholder, technology and pipeline analysis

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Degrader-Antibody Conjugates 2024: A Landscape Analysis of Stakeholders, Technologies, Pipeline and Partnering from an Industry Perspective

Aflibercept (Eylea) Biosimilars Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Antibody Target, Technology & Pipeline Database: 1-Year Subscription

FcRn Inhibitors Pipeline Review